Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01947140 · OUTCOME

Progression Free Survival (PFS) of Subjects in Phase 1

Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies · Source last updated 2026-09-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
Inter-Quartile Range
Time frame
Up to 1.5 years

What was measured

PFS is defined as the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. In a clinical trial, measuring the PFS is one way to see how well a new treatment works.

Analysis population: Pre-specified to report all Phase 1 data as a single Arm

Groups in this outcome

Phase I

Includes all subjects in Cohorts 1 through 5 of Phase 1 of the study who received a combination of pralatrexate and romidepsin.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Phase I29

Reported measurements

Source class 1
Values in months · Interval/dispersion: Inter-Quartile Range
GroupValueSpreadLowerUpperComment
Phase I3.7Not reported1.410.8Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.4
        upper Limit
        10.8
        value
        3.7
denoms
  1. counts
    1. group Id
      OG000
      value
      29
    units
    Participants
description
PFS is defined as the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. In a clinical trial, measuring the PFS is one way to see how well a new treatment works.
dispersion Type
Inter-Quartile Range
groups
  1. description
    Includes all subjects in Cohorts 1 through 5 of Phase 1 of the study who received a combination of pralatrexate and romidepsin.
    id
    OG000
    title
    Phase I
param Type
MEDIAN
population Description
Pre-specified to report all Phase 1 data as a single Arm
reporting Status
POSTED
time Frame
Up to 1.5 years
title
Progression Free Survival (PFS) of Subjects in Phase 1
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-d643ffaf417bcef6d45eb5e0

Preserved source evidence · Not medical advice